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Background: The cytoskeletal organizer ezrin is a member of the ezrin-radixin-moesin (ERM) family and plays
important roles in not only cell motility, cell adhesion, and apoptosis, but also in various cell signaling pathways.
Phosphorylation at Thr-567 and Tyr-353 are key regulatory events in the transition of the dormant to active form of
ezrin. This study investigated the prognostic implications of ezrin and phosphorylated ezrin (p-ezrin) expression in
non-small cell lung carcinoma (NSCLC).
Methods: Ezrin and p-ezrin protein expressions were examined by immunohistochemistry in 150 NSCLC and adjacent
non-tumor tissues and 14 normal lung tissues. qRT-PCR was used to determine ezrin mRNA expression levels in fresh
tissues. The correlations between overexpression of ezrin and p-ezrin and the clinicopathological features of NSCLC
were analyzed. The survival rates were calculated by the Kaplan-Meier method for 108 NSCLC cases.
Results: Ezrin and ezrinThr-567 proteins showed cytosolic and membranous staining patterns; however, ezrinTyr-353
protein only showed cytosolic staining. Ezrin and p-ezrin were significantly upregulated in NSCLC compared with the
normal counterparts. Increased ezrin, ezrinThr-567, and ezrinTyr-353 levels were correlated with the late stage and poor
differentiation of NSCLC. However, only ezrinThr-567 was correlated with the presence of lymph node metastasis. In
regard to survival, only ezrinThr-567 was related with the overall survival time of patients with NSCLC, and both ezrin and
ezrinThr-567 were associated with shortened survival time for patients with early stage NSCLC.
Conclusions: Ezrin and p-ezrin, especially ezrinThr-567, may prove to be useful as a novel prognostic biomarker of NSCLC.
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Lung cancer is a leading cause of cancer-related death
worldwide, with over one million cases diagnosed each
year [1]. Approximately 85% of lung cancers are non-small
cell lung cancer (NSCLC) [2]. Molecular target therapy is
one of the promising field of NSCLC treatment, and its tar-
get includes EGFR (epidermal growth factor receptor),
EML4-ALK (echinoderm microtubule associated protein
like4-anaplastic lymphoma kinase). EGFR TKI (gefitinib
and erlotinib) and EML4/ALK inhibitor (Crizotinib) have* Correspondence: xim918@sina.com; zhlin720@ybu.edu.cn
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unless otherwise stated.achieved better results in the clinical therapy of advanced
NSCLC [3,4]. Despite progress in the multimodality treat-
ment of lung cancer, prognosis is still poor, with 10–15%
5-year survival rates. More than 90% of deaths from
NSCLC are attributable to metastases [5].
The cytoskeletal organizer ezrin was first identified as an
important metastatic regulator in rhabdomyosarcoma and
osteosarcoma [6,7]. Ezrin is a member of the ezrin-radixin-
moesin (ERM) family and acts as a cross-linker between
the plasma membrane and the actin cytoskeleton [8]. In its
inactive form, ezrin is located in the cytoplasm and its C-
terminal domain, an F-actin-binding site, is masked by the
N-terminal domain of ezrin or other ERM family member
proteins. Once ezrin is activated by threonine and tyrosine
phosphorylation, it assumes an active form, in which its N-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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terminal domain binds to F-actin [8,9]. Ezrin plays im-
portant roles not only in cell motility, cell adhesion, and
apoptosis, but also in various cell signaling pathways.
Ezrin is synthesized in a dormant form in which the N-
terminal domain in bound to the C-terminal domain,
thus mutually blocking their capacity to bind other
molecules [10].
Phosphatidylinositol 4, 5-bisphosphate (PIP2) bind-
ing and the phosphorylation of threonine 567 (Thr-
567) and tyrosine 353 (Tyr-353) in ezrin are involved
in the switching of ezrin from the dormant form to
its active state. Once phosphorylated, ezrin binds more
tightly to the membrane. Phosphorylated ezrin (p-ezrin) is
often associated with the stimulation of cellular func-
tions. Phosphorylation of Tyr-353 in ezrin is regulated
through the PI3-kinase/Akt pathway, and phosphoryl-
ation of Thr-567 depends on the p38 MAP-kinase activ-
ity, and these phosphorylation events promote tumor
amplification, metastasis and invasion. Phosphorylation
of Thr-567 and Tyr-353 are key events that regulate the
transition from the dormant state of ezrin to its active
form [11]. These findings suggest that phosphorylated
ezrin might be a potential molecular target for cancer
therapy.
A few studies to date have reported an association be-
tween ezrin/p-ezrin expression and clinicopathological pa-
rameters, as well as its prognostic role in lung cancer.
Thus, we analyzed the expression and localization of ezrin/
p-ezrin in NSCLC compared with the normal counterparts,
determined its relationship with clinicopathological param-
eters, and investigated its prognostic value for NSCLC pa-
tients based on tumor stage and survival data. We found
that ezrin and p-ezrin (ezrinThr-567 and ezrinTyr-353) are fre-
quently upregulated in NSCLC compared with the normal
counterparts, and are related with the poor differentiation
and late clinical stage of NSCLC. However, only ezrinThr-567
was related with the presence of lymph node metastasis
and the overall survival time of NSCLC patients, indicating
that ezrin, especially ezrinThr-567, may prove to be useful as
a novel prognostic biomarker of NSCLC.Methods
Ethics statement
This study complied with the Helsinki Declaration and
was approved by the Human Ethics and Research Ethics
committees of Yanbian University Medical College in
China. Through the surgery consent form, patients were
informed that resected specimens were stored by the
hospital and potentially used for scientific research, and
that their privacy would be maintained. Follow-up sur-
vival data were collected retrospectively through medical
record analyses.Clinical samples
A total of 150 NSCLC tissue microarray samples, including
82 cases of lung adenocarcinoma and 68 cases of lung
squamous cell carcinomas (SCCs), were collected from
Shanghai Outdo Biotech Co. Ltd. between Dec. 2004 and
Jan. 2008. (Outdo Biotech) and Affiliated Hospital of
Chengde Medical College. All cases of NSCLC used in this
study were primary tumor, and were not treated before sur-
gery. Fourteen cases of normal lung tissue were obtained
from autopsy samples in Yanbian University Medical Col-
lege. All tissues were routinely fixed in 10% buffered forma-
lin and embedded in paraffin blocks.
The pathological parameters, including age, gender,
tumor size, clinical stage, differentiation and the presence
of nodal metastasis, were carefully reviewed in all 150 sam-
ples. The patients’ age ranged from 36 to 78 years, with a
mean age of 60.2 years. The male to female ratio was
112:38. TNM staging was assessed according to the staging
system established by the American Joint Committee on
Cancer (AJCC 7th edition). Of the 150 NSCLC cases, 54
cases were TNM stage I (TNM stage IA = 14, TNM stage
IB = 40), 44 cases were TNM stage II (TNM stage IIA = 35,
TNM stage IIB = 9), 45 cases were TNM stage III (TNM
stage IIIA = 34, TNM stage IIIB = 11), and 7 cases were
TNM stage IV. Thirty-four cases were well differentiated,
89 cases were moderately differentiated, and 27 cases were
poorly differentiated. Of the 150 NSCLC samples, 96 cases
were lymph node (LN) metastasis-negative, and 54 cases
were LN metastasis-positive. A total 108 of NSCLC pa-
tients had follow-up records for more than 5 years, and the
follow-up deadline was March 2012. By March 2012, 54
patients had died while 54 patients remained alive. The
median survival time was 43.2 months. The survival time
was counted from the date of surgery to the follow-up
deadline, or date of death (all of them died of cancer recur-
rence or metastasis).
Immunohistochemistry for ezrin and p-ezrin in
paraffin-embedded tissues
The Dako LSAB kit (Dako, Glostrup, Denmark) was
used for immunohistochemistry. Serial 4 μm-thick tis-
sue sections were prepared on silane-coated slides
(Sigma, St. Louis, MO, USA), and deparaffinized, rehy-
drated and incubated with 3% H2O2 in methanol for
10 min at room temperature to eliminate endogenous
peroxidase activity. The antigen was retrieved at 95°C
for 20 min by placing the slides in 10 mM sodium cit-
rate buffer (pH 6.0). The slides were then incubated
with primary antibodies against ezrin (1:50, #3145;
anti-rabbit polyclonal antibody, Cell Signaling Technol-
ogy, Boston, USA), ezrinTyr-353 (1:150, #11063, anti-
rabbit polyclonal antibody, Signalway Technology,
Maryland, USA), and ezrinThr-567, (1:150, #11202, anti-
rabbit polyclonal antibody, Signalway Technology) at 4°C
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30 min with biotinylated secondary antibody, the slides
were incubated with streptavidin-peroxidase complex at
room temperature for 30 min. Immunostaining was de-
veloped using chromogen, 3,3′-diaminobenzidine, and
counterstained with Mayer’s hematoxylin. Rabbit IgG
isotope was used as control and the results were nega-
tive. Positive tissue sections were processed without pri-
mary antibody as negative controls.Evaluation of immunohistochemical staining
All slides were evaluated independently by two pathol-
ogists without knowledge of clinical outcome. The in-
terpretation criteria were previously described by
Elzagheid A et al. [12] and Lin L et al. [13]. Combined
the staining intensity, the immunostaining for ezrin/p-
ezrin was mainly semi-quantitatively scored as ‘-’
(negative, no or less than 5% positive cells), ‘+’ (5–25%
positive cells), ‘++’ (26–50% positive cells) and ‘+++’
(more than 50% positive cells). The ‘strongly positive’
descriptor was used to describe ‘++’ and ‘+++’ scored
cells. For survival analysis, ezrin/p-ezrin expression
level was denoted as high expression (‘++’ and ‘+++’)
or low expression (‘-’ and ‘+’).Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was extracted using Trizol reagent (Invitrogen,
Carlsbad, CA) from 21 NSCLC fresh tissue samples, 15
adjacent lung tissues and 8 normal tissue counterparts.
First-strand cDNA was synthesized by PrimeScript reverse
transcriptase (TaKaRa Bio, Dalian, China) and oligo (dT)
following the manufacturer’s instructions. Real-time PCR
was performed using double-stranded DNA-specific SYBR
Premix Ex TaqTM II Kit (TaKaRa Bio) on a Bio-Rad se-
quence detection system according to the manufacturer’s
instructions. Double-stranded DNA specific expression
was tested by the comparative Ct method using 2-ΔΔCt.
Ezrin primers were as follows: 5′-TGGAGTTGATGCCC
TTGGAC-3′ and 5′-AGTCAGGTGCCTTCTTGTCG-3′.
GAPDH primers were as follows: 5′-CATCACCATCTT
CCAGGAGCG-3′ and 5′-TGACCTTGCCCACAGCCT
TG-3′. All assays were performed in triplicate at least
three times.Statistical analysis
Statistical analysis was performed using the Chi-square
(x2-test) test, Mann–Whitney test and Kaplan–Meier
test and the SPSS software program for Windows, ver-
sion 17.0 (SPSS, Chicago, USA). A P-value less than 0.05
was considered as statistically significant.Results
Quantification of ezrin, ezrinThr-567 and ezrinTyr-353
overexpression in NSCLC by immunohistochemistry
and qRT-PCR
We first performed immunohistochemistry for ezrin,
ezrinThr-567 and ezrinTyr-353 in 150 samples of paraffin-
embedded NSCLC samples, 150 adjacent lung tissues and
14 normal tissue counterparts. Ezrin and ezrinTyr-353
showed mainly cytoplamic staining, while ezrinThr-567
showed cytosolic and membranous staining patterns in
NSCLC samples. Ezrin and p-ezrin (both Thr-567 and
Tyr-353) proteins showed significantly higher levels in
NSCLC samples compared with adjacent non-tumor and
normal lung tissues. The percentages of positive ezrin,
ezrinThr-567 and ezrinTyr-353 cells in adjacent non-tumor tis-
sues were 31.3%, 14.0% and 11.3%, respectively, and 35.7%,
14.3% and 7.1% in normal lung tissue counterparts, respect-
ively. However, the rates of positive ezrin, ezrinThr-567 and
ezrinTyr-353 expression were significantly higher in NSCLC
than in the adjacent non-tumor tissues and normal lung tis-
sue counterparts, with rates of 62.7%, 63.3% and 71.3% in
NSCLC, respectively (P < 0.01). The percentages of strongly
positive ezrin, ezrinThr-567 and ezrinTyr-353 cells were 40.7%,
45.3% and 48.0% in NSCLC, respectively, and were also sig-
nificantly higher than in adjacent non-tumor tissues and
normal tissue counterparts (P < 0.01). In contrast, in adja-
cent non-tumor tissues, the percentages of cells with
strongly positive ezrin, ezrinThr-567 and ezrinTyr-353 expres-
sion were 3.3%, 4.7% and 1.3%, respectively, and completely
negative in normal lung tissue counterparts (Table 1 and
Figure 1).
qRT-PCR data confirmed increased levels of ezrin
mRNA expression in NSCLC samples compared with ad-
jacent non-tumor tissues and normal tissue counterparts
in fresh tissues (Figure 2).
Association between overexpression of ezrin, ezrinThr-567
and ezrinTyr-353 proteins and clinical parameters of NSCLC
Ezrin, ezrinThr-567 and ezrinTyr-353 overexpression signifi-
cantly correlated with the poor differentiation and late
clinical stage of NSCLC. The percentages of positive ezrin,
ezrinThr-567 and ezrinTyr-353 cells were significantly higher
in poorly differentiated NSCLC cases (85.2%, 88.9% and
92.6%, respectively) compared with well differentiated
NSCLC (50.0%, 47.1% and 61.8%, respectively) and moder-
ately differentiated NSCLC cases (60.7%, 61.8% and 68.5%,
respectively) (P < 0.01). For the TNM clinical stage, the
percentages of positive ezrin, ezrinThr-567 and ezrinTyr-353
cells in advanced stage (III-IV) of NSCLC were 82.7%,
75.0% and 92.3%, respectively. These levels were much
higher than in cases of early stage (I–II) (52.0%, 57.1% and
60.2%, respectively) (P < 0.01, P < 0.05 and P < 0.01, re-
spectively). Interestingly, only ezrinThr-567 overexpression
was significantly correlated with the presence of LN
Table 1 Expression of ezrin, ezrinThr-567 and ezrinTyr-353 in NSCLC
Ezrin EzrinThr-567 EzrinTyr-353
Diagnosis No. of cases Positive rate Strongly positive rate Positive rate Strongly positive rate Positive rate Strongly positive rate
(+ ~ +++, %) (++ ~ +++, %) (+ ~ +++, %) (++ ~ +++, %) (+ ~ +++, %) (++ ~ +++, %)
NSCLC 150 94 (62.7%)** 61 (40.7%)** 95 (63.3%)** 68 (45.3%)** 107 (71.3%)** 72 (48.0%)**
Adjacent
non-tumor
150 47 (31.3%) 5 (3.3%) 21 (14.0%) 7 (4.7%) 17 (11.3%) 2 (1.3%)
Normal lung
tissues
14 5 (35.7%) 0 (0.0%) 2 (14.3%) 0 (0.0%) 1 (7.1%) 0 (0.0%)
Positive rate: percentage of positive cases with ‘+’, ‘++’, and ‘+++’, Strongly positive rate: percentage of positive cases with ‘++’, and ‘+++’, **P < 0.01: NSCLC vs
Adjacent non-tumor and Normal lung tissues.
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cells in NSCLC with LN metastasis was 79.6% (43/54), and
this was statistically higher than in cases without LN metas-
tasis (54.2%, 52/96) (P < 0.01), indicating that ezrinThr-567
might be more accurate than ezrin or ezrinTyr-353 as a
marker for poor prognosis for NSCLC. Additionally, the ex-
pression status of ezrin, ezrinThr-567 and ezrinTyr-353 pro-
teins was not correlated with age, gender or tumor size of
patients with NSCLC (Table 2).Figure 1 Ezrin and p-ezrin protein expression in NSCLC and normal c
tissues. (B) Positive ezrin expression in the cytoplasm of normal columnar epit
(C) Positive ezrin expression in the cytoplasm of adenocarcinoma cells of lung
squamous cell carcinomas (SCCs). (E, F) Negative ezrinThr567 expression in nor
expression of ezrinThr567 in the cytoplasm of lung adenocarcinoma. The positi
expression of ezrinThr567 in the cytoplasm and membranes of lung SCCs. (I, J)
non-tumor tissues. (K) Strong expression of ezrinTyr353 in the cytoplasm of lun
of lung SCCs. Magnification 200× in A–L.Evaluation of ezrin and p-ezrin as a potential prognostic
marker for NSCLC by Kaplan–Meier test
A total 108 of NSCLC patients were identified for analysis
of prognostic evaluation. The data showed that elevated
ezrinThr-567 was significantly related with shorter survival
times (P = 0.019, log-rank). However, ezrin and ezrinTyr-353
expression statuses were not related with the overall sur-
vival times of patients with NSCLC (P = 0.076 and P =
0.093, respectively, log-rank) (Figure 3).ounterparts. (A) Negative ezrin protein expression in normal lung
helia (red arrows) of terminal bronchiole in adjacent non-tumor tissues.
. (D) Strong positive expression of ezrin protein in the cytoplasm of
mal lung tissues and adjacent non-tumor tissues. (G) Strong positive
ve signals were concentrated in the perinucleus. (H) Strong positive
Negative ezrinThr353 expression in normal lung tissues and adjacent
g adenocarcinomas. (L) Strong expression of ezrinTyr353 in the cytoplasm
Figure 2 Ezrin mRNA expression in NSCLC and normal
counterparts. qRT-PCR analysis of ezrin mRNA in NSCLC, adjacent and
normal tissues. Ezrin mRNA expression levels were significantly higher
in NSCLCs compared with the adjacent non-tumor and normal lung
fresh tissues. Experiments were performed in triplicate for each case.
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NSCLC and 33 were advanced stage. For patients with early
stage (I–II) NSCLC, the survival analysis demonstrated that
high ezrin and ezrinThr-567 levels were associated with lower
overall survival rate (P = 0.016 and P = 0.045, respectively,
log-rank) (Figure 4). However, ezrinTyr-353 status was notTable 2 Correlation between overexpression of ezrin, ezrinThr-56
Ezrin
Parameters No. of cases n (%) P
Gender 0.062
Male 112 75 (67.0)
Female 38 19 (50.0)
Age 0.077
≧60 99 67 (67.7)
<60 51 27 (52.9)
Tumor size 0.283
T1-2 119 72 (60.5)
T3-4 31 22 (71.0)
Stage 0.000**
I-II 98 51 (52.0)
III-IV 52 43 (82.7)
Differentiation 0.007a**
Well 34 17 (50.0)
Moderate 89 54 (60.7)
Poor 27 23 (85.2)
LN metastasis 0.318
Negative 96 63 (65.6)
Positive 54 31 (57.4)
*P < 0.05; **P < 0.01; a: Poorly vs Well and moderately differentiated tumors.correlated with the survival rate of patients with early stage
NSCLC. Additionally, the expression statuses of ezrin,
ezrinThr-567 and ezrinTyr-353 proteins were not correlated
with the survival rate in patients with advanced stage
(III–IV) NSCLC (data not shown, P = 0.104, P = 0.288,
P = 0.713, respectively, log-rank).
Discussion
The human ezrin gene maps to chromosome 6q25.2-q26
and the total length of the mRNA is 3166 bp, encoding
585 amino acids [6]. Ezrin is known to be a component
of cell surface structures that are involved in cell adhe-
sion to the extracellular matrix, as well as in cell-cell in-
teractions, receptor tyrosine kinase signaling, signal
transduction through Rho GTPase and interactions with
Akt-mediated cellular apoptotic machinery [14,15]. It is
present in the cytoplasm in an inactive form but after
threonine and tyrosine phosphorylation, ezrin assumes an
active form, moving to the cell membrane and tethering
F-actin to the cell membrane [8]. Recent studies showed
that ezrin likely regulates adhesion molecules and partici-
pates in cell signal transduction and other channels in
these processes [6,16].
In previous studies, ezrin was found to have important
roles in the tumorigenesis and metastasis of several malig-
nancies. Khanna et al. [6] showed that high ezrin expression7 and ezrinTyr-353 proteins and clinical parameters of NSCLC
EzrinThr-567 EzrinTyr-353
n (%) P n (%) P
0.45 0.230
69 (61.6) 77 (68.8)
26 (68.4) 30 (78.9)
0.642 0.364
64 (64.6) 73 (73.7)
31 (60.8) 34 (66.7)
.791 0.620
76 (63.9) 86 (72.3)
19 (61.3) 21 (67.7)
.031* 0.000**
56 (57.1) 59 (60.2)
39 (75.0) 48 (92.3)
0.002a** 0.006a**
16 (47.1) 21 (61.8)
55 (61.8) 61 (68.5)
24 (88.9) 25 (92.6)
0.002** 0.578
52 (54.2) 67 (69.8)
43 (79.6) 40 (74.1)
Figure 3 Kaplan-Meier survival curves illustrating the significance of ezrin and p-ezrin expressions in NSCLCs. NSCLC patients with high
ezrinThr567 levels had a lower overall survival rate compared with NSCLC patients with low ezrinThr567 levels (log-rank P = 0.019). However, both
ezrin and ezrinTyr353 were not related with the overall survival of patients with NSCLC (log-rank P = 0.076, log-rank P = 0.093, respectively).
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poor outcome in osteosarcoma. Xie et al. [17] reported that
ezrin affected the growth and invasiveness of esophageal
SCC cells through the MAPK and transforming growth fac-
tor β pathway. However, Moilanen et al. found that serous
ovarian cancer with low expression of ezrin protein had
poor prognosis [18]. Karmakar et al. [19] also reported that
the invasion of choriocarcinoma cells actually strengthened
when ezrin protein expression decreased. Here we also
found that ezrin was significantly upregulated in NSCLC
compared with the adjacent non-tumor tissues and normal
lung tissue counterparts (P < 0.01). Ezrin overexpression
was significantly correlated with the advanced clinical stage
and poor differentiation of NSCLC (P < 0.01), but no correl-
ation was found with lymph node metastasis and invasion
of NSCLC in our data. However, Zhang et al. [20] reported
that ezrin expression was significantly associated with in-
creased tumor stage and LN metastasis of NSCLC. These
studies suggested that there might be cell- and tissue-
specific functions for ezrin in tumor progression.
To date, two important phosphorylation sites in ezrin
have been identified: ezrinThr567 and ezrinTyr353. Ezrin dir-
ectly interacts with signaling enzymes such as phosphoino-
sitide 3-kinase (PI3-kinase), and the phosphorylated
tyrosine 353 (Tyr-353) residue of ezrin is regulated throughFigure 4 Kaplan-Meier survival curves illustrating the significance of e
NSCLCs (stages I–II, n = 98), patients with high ezrin and ezrinThr567 levels h
those with low ezrin and ezrinThr567 levels (log-rank P = 0.030), respectively.
early-stage NSCLC.the PI3-kinase/Akt pathway [14]. Ezrin is also preferentially
degraded and resynthesized after the phosphorylation at
threonine 567 (Thr-567) depends on the p38 MAP-kinase
activity [21]. Phosphorylation at Thr-567 has received a
great deal of attention, as this phosphorylation event is be-
lieved to relieve the N- to C-terminal binding of ezrin,
transforming ezrin into an active state with domains ac-
cessible for binding to membrane and F-actin [22]. This
suggests that ezrinThr-567 alters ezrin molecule plasticity,
and it is associated with numerous biological behaviors.
Chen et al. [23] revealed that ezrinThr-567 has an important
role in liver cancer metastasis. Krishnan et al. [24] found
that transfection of the ezrin-Thr-567A mutant blocked
the ezrinThr-567-inhibited metastases in Ewing’s sarcoma,
suggesting that ezrinThr-567 is closely related to malignancy
metastasis. Additionally, ezrinTyr-353 has been known to be
related to subunit p85, which activates the PI3K/Akt path-
way and plays an important role in modulating tumor cell
survival, invasion, and metastasis. Cui et al. [25] reported
that expression of ezrinTyr-353 correlated with less tumor
differentiation and the presence of lymph node metastasis
in pancreatic cancer. Lan et al. [26] found that induction of
p-ezrin via the p38 MAP kinase signaling pathway was in-
volved in the formation of microvilli during development
of epithelial cell polarization. However, few reports to datezrin and p-ezrin expression in early-stage NSCLCs. In early-stage
ad significantly reduced NSCLC-specific overall survival rates relative to
However, ezrinTyr353 was not related with the survival of patients with
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p-ezrin in NSCLC. Zhang et al. [20] revealed that p-ezrin
expression was significantly higher in NSCLC than in nor-
mal lung tissues, and was closely correlated with clinical
stage and LN metastasis in NSCLC. In the present study,
we found that p-ezrin exhibited cytosolic and membranous
staining patterns in NSCLC, and the percentages of
ezrinThr-567 and ezrinTyr-353 expression were significantly
higher in NSCLC than in adjacent non-tumor tissues and
normal tissue counterparts (P < 0.01). Interestingly, we
found that total ezrin staining was lower than p-ezrin stain-
ing. Similarly, Oda et al. revealed that the expression rate of
the ezrin was 42.5%, but 55.0% for ezrinTyr353 and 42.5% for
ezrinTyr354 in intraductal papillary mucinous neoplasms of
pancreas. Moreover, ezrin expression rate was 32.4%, but
higher for ezrinTyr353 (41.2%) in intestinal-type pancreatic
neoplasms [27]. Cui et al. and Di Cristofano et al. also re-
ported the similar conclusions in pancreatic cancer and
osteosarcoma, respectively [25,28]. The cause might be re-
lated with that some cases mainly expressed p-ezrin, but
showed lower ezrin level or not, suggesting that although
total ezrin is sum of p-ezrin and non-phosphorylated ezrin
in cell level, it is not suitable in the case study. It needs the
further study to verify the detailed mechanism.
Among the clinicopathological features, both ezrinThr-567
and ezrinTyr-353 protein overexpression were significantly
correlated with the poor differentiation and late clinical
stage of NSCLC (P < 0.01). However, only ezrinThr-567 over-
expression was significantly correlated with the presence of
lymph node metastasis, suggesting that ezrinThr-567 was im-
portant for the invasion and metastasis processes in
NSCLC. Interestingly, Orr et al. [29] recently found that
EGF can induce ezrin phosphorylation (Thr567) via activa-
tion of the SK/S1P pathway, and Antelmi et al. [30] re-
vealed that p-ezrin was almost exclusively expressed in
invadopodia lipid rafts where it co-locolized in a functional
complex with EGFR and β1-integrin in metastatic breast
cancer cell line MDA-MB-231, suggesting that ezrin might
be related with EGF and EGFR in cancer progression.
These results impelled us to study the detailed mechanism
of the correlation between EGFR and ezrin, and whether
EGFR-TKI can suppress the metastasis of NSCLC via ezrin
phosphorylation in future.
In regard to survival, Zhang et al. [20] showed that
ezrin-positive expression independently predicted inferior
overall survival and disease-free survival. Additionally,
ezrin overexpression was helpful to predict the poor sur-
vival of patients with early stage of NSCLC. Cui et al. [25]
also found that overall survival of patients with pancreatic
cancer was significantly associated with ezrinTyr-353, but
not with total ezrin or ezrinThr-567. However, Di Cristofano
et al. [28] reported no statistical significance regarding the
relationship between p-ezrin expression and survival time
in osteosarcoma. Here we demonstrated that ezrinTyr-353has no correlation with the survival of patients with
NSCLC. However, ezrinThr-567 expression was significantly
correlated with adverse outcomes with respect to overall
survival time, and both ezrin and ezrinThr-567 overexpres-
sions were correlated with shorter survival time in patients
with early stage NSCLC. The high proportion and prog-
nostic value of ezrin and ezrinThr-567 expression in NSCLC
suggested that ezrin, especially ezrinThr-567, could be a po-
tential biomarker for NSCLC. However, more extensive
investigations are needed to clarify the exact roles of ezrin
and ezrinThr-567 in the development and progression of
NSCLC.
Conclusions
Ezrin, ezrinThr-567 and ezrinTyr-353 were all significantly up-
regulated in NSCLC compared with normal tissues, and
all correlated with the poor differentiation and late clinical
stage of NSCLC. However, only ezrinThr-567 overexpres-
sion correlated with the presence of lymph node metasta-
sis of NSCLC. Additionally, ezrinThr-567 correlated with
the overall survival time of patients with NSCLC, and both
ezrin and ezrinThr-567 overexpression were correlated with
shorter survival time in patients with early stage NSCLC.
In this regard, ezrin, especially ezrinThr-567, may prove to
be useful as a novel prognostic biomarker of NSCLC.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JT, JJ, LX and SY participated in study conception, design, case selection and
experiments. JT, SX and ZS carried out the data collection. JT, YK and LZ
performed the scoring of immunohistochemical staining. JT, PY, SX and LZ
performed data analysis and writing of the manuscript. All the authors read
and approved the final manuscript.
Acknowledgements
This study was supported by grants from the National Natural Science Funds
of China (61371067) and The Projects of Research & Innovation of Jilin Youth
Leader and Team (20130521017JH).
Author details
1Department of Pathology & Cancer Research Center, Yanbian University
Medical College, Yanji 133002, China. 2Department of Internal Medicine,
Yanbian University Hospital, Yanji 133000, China. 3Department of Oncology,
Yanbian University Hospital, Yanji 133000, China. 4Department of Anatomy,
Medical School, Institute for Medical Sciences, Chonbuk National University,
Jeonju 561-756, Republic of Korea.
Received: 13 October 2013 Accepted: 5 March 2014
Published: 15 March 2014
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007.
CA Cancer J Clin 2007, 57:43–66.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T,
Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M,
Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics 2012.
CA Cancer J Clin 2012, 62:220–241.
3. Chen X, Liu Y, Røe OD, Qian Y, Guo R, Zhu L, Yin Y, Shu Y: Gefitinib or erlotinib
as maintenance therapy in patients with advanced stage non-small cell
lung cancer: a systematic review. PLoS One 2013, 8(3):e59314.
Jin et al. BMC Cancer 2014, 14:191 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/1914. Gaughan EM, Costa DB: Genotype-driven therapies for non-small cell lung
cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med
Oncol 2011, 3(3):113–125.
5. Lee HW, Kim EH, Oh MH: Clinicopathologic implication of ezrin expression in
non-small cell lung cancer. Korean J Pathol 2012, 46(5):470–477.
6. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C,
Gorlick R, Hewitt SM, Helman LJ: The membrane-cytoskeleton linker ezrin
is necessary for osteosarcoma metastasis. Nat Med 2004, 10(2):182–186.
7. Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, Wang L: Down-regulation of
miR-183 promotes migration and invasion of osteosarcoma by targeting
ezrin. Am J Pathol 2012, 180(6):2440–2451.
8. Bretscher A, Edwards K, Fehon RG: ERM proteins and merlin: integrators at
the cell cortex. Nat Rev Mol Cell Biol 2002, 3:586–599.
9. Turunen O, Wahlström T, Vaheri A: Ezrin has a COOH-terminal
actin-binding site that is conserved in the ezrin protein family. J Cell Biol
1994, 126:1445–1453.
10. Liu Y, Belkina NV, Park C, Nambiar R, Loughhead SM, Patino-Lopez G, Ben-Aissa K,
Hao JJ, Kruhlak MJ, Qi H, von Andrian UH, Kehrl JH, Tyska MJ, Shaw S:
Constitutively active ezrin increases membrane tension, slows
migration, and impedes endothelial transmigration of lymphocytes
in vivo in mice. Blood 2012, 119(2):445–453.
11. Fievet BT, Gautreau A, Roy C, Del Maestro L, Mangeat P, Louvard D, Arpin M:
Phosphoinositide binding and phosphorylation act sequentially in the
activation mechanism of ezrin. J Cell Biol 2004, 164:653–659.
12. Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A,
Syrjänen K, Pyrhönen S, Carpén O: Intense cytoplasmic ezrin
immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol
2008, 39(12):1737–1743.
13. Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J, Lin Z: DEK over expression as
an independent biomarker for prognosis in colorectal cancers.
BMC Cancer 2013, 13:366.
14. Gautreau A, Poullet P, Louvard D, Arpin M: Ezrin, a plasma membrane-
microfilament linker, signals cell survival through the phosphatidylinositol
3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999, 96(13):7300–7305.
15. Martin GS: Cell signaling and cancer. Cancer Cell 2003, 4(3):167–174.
16. McClatchey AI: Merlin and ERM proteins: unappreciated roles in cancer
development? Nat Rev Cancer 2003, 3(11):877–883.
17. Xie JJ, Xu LY, Xie YM, Zhang HH, Cai WJ, Zhou F, Shen ZY, Li EM: Roles of
ezrin in the growth and invasiveness of esophageal squamous
carcinoma cells. Int J Cancer 2009, 124(11):2549–2558.
18. Moilanen J, Lassus H, Leminen A, Vaheri A, Bützow R, Carpén O: Ezrin
immunoreactivity in relation to survival in serous ovarian carcinoma
patients. Gynecol Oncol 2003, 90(2):273–281.
19. Karmakar S, Das C: Modulation of ezrin and E-cadherin expression by
IL-1beta and TGF-beta1 in human trophoblasts. J Reprod Immunol 2004,
64(1–2):9–29.
20. Zhang XQ, Chen GP, Wu T, Yan JP, Zhou JY: Expression and clinical
significance of ezrin in non-small cell lung cancer. Clin Lung Cancer 2012,
13(3):196–204.
21. Grune T, Reinheckel T, North JA, Li R, Bescos PB, Shringarpure R, Davies KJ:
Ezrin turnover and cell shape changes catalyzed by proteasome in
oxidatively stressed cells. FASEB J 2002, 16(12):1602–1610.
22. Zhu L, Zhou R, Mettler S, Wu T, Abbas A, Delaney J, Forte JG: High turnover
of ezrin Thr567 phosphorylation: conformation, activity, and cellular
function. Am J Physiol Cell Physiol 2007, 293(3):874–884.
23. Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X,
Liao J, Ward T, Xia P, Emenari C, Ding X, Thompson W, Ma K, Zhu J,
Aikhionbare F, Dou K, Cheng SY, Yao X: Rho kinase phosphorylation
promotes ezrin-mediated metastasis in hepatocellular carcinoma.
Cancer Res 2011, 71:1721–1729.
24. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ: Ezrin
mediates growth and survival in Ewing’s sarcoma through the AKT/
mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006,
23:227–236.
25. Cui Y, Li T, Zhang D, Han J: Expression of ezrin and phosphorylated
ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest
2010, 28(3):242–247.
26. Lan M, Kojima T, Murata M, Osanai M, Takano K, Chiba H, Sawada N:
Phosphorylation of ezrin enhances microvillus length via a p38 MAP-
kinase pathway in an immortalized mouse hepatic cell line. Exp Cell Res
2006, 312(2):111–120.27. Oda Y, Aishima S, Morimatsu K, Hayashi A, Shindo K, Fujino M, Mizuuchi Y,
Hattori M, Tanaka M, Oda Y: Differential ezrin and phosphorylated ezrin
expression profiles between pancreatic intraepithelial neoplasia,
intraductal papillary mucinous neoplasm, and invasive ductal carcinoma
of the pancreas. Hum Pathol 2013, 44(8):1487–1498.
28. Di Cristofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A,
Petrozza V, Della Rocca C: Phosphorylated ezrin is located in the nucleus
of the osteosarcoma cell. Mod Pathol 2010, 23(7):1012–1020.
29. Orr Gandy KA, Adada M, Canals D, Carroll B, Roddy P, Hannun YA, Obeid LM:
Epidermal growth factor-induced cellular invasion requires sphingosine-1-
phosphate/sphingosine-1-phosphate 2 receptor-mediated ezrin activation.
FASEB J 2013, 27(8):3155–3166.
30. Antelmi E, Cardone RA, Greco MR, Rubino R, Di Sole F, Martino NA, Casavola V,
Carcangiu M, Moro L, Reshkin SJ: ß1 integrin binding phosphorylates ezrin at
t567 to activate a lipid raft signalsome driving invadopodia activity and
invasion. PLoS One 2013, 8(9):e75113.
doi:10.1186/1471-2407-14-191
Cite this article as: Jin et al.: Prognostic implications of ezrin and
phosphorylated ezrin expression in non-small cell lung cancer. BMC Cancer
2014 14:191.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
